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Post-kala-azar dermal leishmaniasis (PKDL) is a common complication of visceral leishmaniasis (VL) caused by
Leishmania donovani. Because of its possible role in transmission it is considered a public health problem in VL
endemic areas. The clinical features include a skin rash consisting of macules, papules or nodules in an otherwise
healthy individual; this presentation is determined by the immune response towards parasites in the skin that
probably persisted from the previous VL episode. The immune response in VL, cured VL and PKDL is the result of
changes in the cytokine profile that only in part can be captured under the Th1 and Th2 dichotomy. Regulatory
T cells and Th 17 cells also play a role. VL is characterized by an absent immune response to Leishmania with
a predominantly Th2 type of response with high levels of IL-10; after successful treatment the patient will be
immune with in vitro features of a Th1 type of response and in vivo a positive leishmanin skin test. PKDL takes an
intermediate position with a dissociation of the immune response between the skin and the viscera, with a Th2
and Th1 type of response, respectively. It is likely that immune responses determine the different epidemiological
and clinical characteristics of PKDL in Asia and Africa; various risk factors for PKDL may influence this, such as
incomplete and inadequate treatment of VL, parasite resistance and genetic factors. It should be noted that PKDL is
a heterogeneous and dynamic condition and patients differ with regard to time of onset after visceral leishmaniasis
(VL), chronicity, extent and appearance of the rash including related immune responses, all of which may vary
over time. Better understanding of these immune responses may offer opportunities for manipulation including
combined chemotherapy and immunotherapy for VL to prevent PKDL from occurring and similarly in the
treatment of chronic or treatment resistant PKDL cases.
Keywords: Post-kala-azar dermal leishmaniasis, PKDL, Visceral leishmaniasis, Immune responses, Clinical features,
Immunosuppression, Immune manipulation
Background
Post-Kala-azar Dermal Leishmaniasis (PKDL) may follow
after treatment of visceral leishmaniasis (VL, kala-azar).
It is an intermediate disease state before full recovery
from VL and is characterized by a skin rash around per-
sisting parasites in the absence of systemic parasitaemia.
Alternatively, reinfection after VL may be considered. It
is thought that these patients may play a role in trans-
mission of VL [1].
After infection with leishmanial parasites through
the bite of the sand fly, individuals may develop VL
with fever, hepatosplenomegaly, weight loss and pan-
cytopenia; typically with high levels of antibodies and
absent cellular immunity against the Leishmania para-
sites. After successful treatment with antileishmanial
drugs the patient becomes immune, as can be demon-
strated in vitro by the cellular immune responses and
in vivo by the leishmanin skin test (LST) that becomes
positive in 80 % of patients [2].
A proportion of treated VL patients may develop
PKDL; these patients are not ill, usually do not have
hepatosplenomegaly and have recovered from the
malnourished state. PKDL is mainly restricted to
follow VL caused by L. donovani; hence it occurs in
Africa and Asia. There are, however, important
epidemiological and clinical differences (Table 1). The
most striking are the differences in clinical presenta-
tion (90 % papular rash in Africa, 90 % macular in
Asia) and the interval between VL and PKDL (0–13
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months in Africa, usually 2–3 years in Asia) [1, 3],
(Figs. 1 and 2). In Africa PKDL is most common in
Sudan; most (85 %) patients self-heal within
12 months; only severe or chronic cases are treated
[3]. In Asia, although there some reports on self-
healing, all patients are treated. After successful
treatment with prolonged courses of antileishmanial
drugs the rash will disappear and patients will
develop immunity similar to cured VL patients. This
immunity is permanent unless there is associated
immunosuppression.
Other patients present with VL and PKDL simultan-
eously (para-kala-azar leishmaniasis); alternatively
around 10 % present with PKDL without a previous
history of VL. In HIV co-infection, the frequency and
clinical presentation of PKDL is different. All these
different manifestations strongly suggest a pivotal role
for the immune response that is influenced by a
number of factors, some of which have been well
described; however, there remain important issues to
be clarified.
In this paper we describe the principal immunological
features of PKDL, in particular in relation to VL, and
correlate these findings with clinical and epidemiological
knowledge. In addition issues in immunosuppression
Table 1 PKDL - differences between Africa and Asia
Asia Africa
Clinical type most common macular papular
Frequency after VL 10–20 % 50–60 %
Infective to sand flies yes yes
Transmission of VL anthroponotic anthroponotic and zoonotic
Interval after VL 0–3 years, or morea 0–13 months
Self-cure yes, probably yes
Occurs without previous VL yes yes
Occurs with VL simultaneouslyb yes yes
Occurs with mucosal involvement yes yes
Treatment policy all are treated chronic > 6 months or severe PKDL are treated
Treatment miltefosine SSG or AmBisome
Marker for cure clinical clinical
arecent data show that up to 30 % of PKDL in Asia occurs within 12 months after treatment for VL
bthis is also called para-kala-azar dermal leishmaniasis
Fig. 1 Typical PKDL from Sudan with papular lesions. ©World
Health Organization, 2012. Reproduced unmodified from
reference [77]
Fig. 2 Typical PKDL from Bangladesh with (confluent) macular rash.
©World Health Organization, 2012. Reproduced unmodified from
reference [77]
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and immunomodulation will be discussed. Lastly, areas
of future research will be outlined.
Immune responses in VL and PKDL
Immune responses in leishmaniasis are often described
in terms of a (T helper) Th1 and Th2 response. This is
derived from the murine model of cutaneous leishman-
iasis in which a dichotomy was found with a Th2 re-
sponse during disease and a Th1 response indicating
cure [4, 5]. In VL in humans this dichotomy is not clear
and shows overlap; disease progression seems deter-
mined mainly by changing cytokine profiles in which the
importance of certain key cytokines varies in the course
of the disease process, in which inhibitors may play an
important role [6]. In addition, other T cell responses
have been identified, such as regulatory T cells and Th17
cells that have been shown to be implicated in various
forms of leishmaniasis [7, 8].
VL
In VL parasites can be found in all organs but particu-
larly in the reticulo-endothelial system; aspirates of
lymph node, bone marrow and spleen are used to dem-
onstrate parasites in VL diagnosis.
Before treatment
After infection in the skin by the sand fly, the innate
immune response includes interaction with neutrophils
and complement after which the parasite infects
macrophages/monocytes. Survival of the parasites is
dependent on inhibition of macrophage activation and
avoiding interaction with T cells [9].
Studies have shown that there is no cellular immune
response against Leishmania parasites: peripheral blood
mononuclear cells (PBMC) do not proliferate in re-
sponse to stimulation with leishmanial parasites; in vivo
the LST is typically negative [10]. This was confirmed in
a later study by measuring cytokines in whole blood as-
says [11]. The cytokine profile in the blood has charac-
teristics of a (anti-inflammatory) Th2 response and
includes IL-6, IL-21 and IL-27 as well as transforming
growth factor beta (TGF-β), sCD14 and tumour necrosis
factor alpha (TNF-α) [12]. IL-6 is associated with lethality
in VL caused by L. infantum [12]. There is a predominant
role of IL-10 and TGF-β that correlate with parasite load
[13–15]. However, during VL also high levels of IL-12
and interferon-γ (INF-γ) can be demonstrated that are
typically associated with a (pro-inflammatory) healing
Th1 response suggesting that there is no Th1 defect in
active VL. The presence of an inhibitory factor such as
IL-10 may be an important marker; blockade of IL-10
in ex vivo assays results in increased IFN-γ and TNF-α
with reduced parasite growth [11, 16]. The complexity
of the immune response cannot be captured in a Th1
and Th2 dichotomy alone [16, 17]. Other T cells that
are implicated in VL include T regulatory cells (CD4+
CD25 +FoxP3 + T regs) that play an important role and
are correlated with high parasite load and production of
IL-10 and TGF-β [15]. The role of Th17 cells is also
important; [18] IL- 17 and IL- 22 that are effectors of
innate immunity, are produced by Th17 cells and are
thought to play a complimentary role to Th1 cytokines
and inhibit parasite growth. This was found to be associ-
ated with resistance to VL, whereas a defect in Th17
responses may increase the risk of VL [19]. The role of
CD8+ T cells is not clear; they may differentiate into
effector cells that may kill target cells such as cyto-
toxic T lymphocytes that also produce TNF and IFN-
γ. Other CD8 cells are memory T cells that may play
a role in protection. Lastly, others acquire a regula-
tory role and are thought to play a role in prevention
of immunopathology [20, 21]. There is a strong
humoral response as evidenced by polyclonal gamma-
globulinaemia; this consists of antileishmanial anti-
bodies that are used in diagnosis such as in the direct
agglutination test (DAT) and the rK39 ELISA. This
humoral response may be stronger in Asia compared
to Africa; the rapid diagnostic test (RDT) based on
detecting rK39 antibodies has excellent sensitivity in
Asia but is less useful in Africa because of lower
levels of antibodies [22]. Other antibodies among the
gammaglobulins include antibodies that can be found
in connective tissue diseases such as SLE; this is
thought to be the result of cross-reaction between
leishmanial antigens and ribonucleotide antigens [23].
After treatment
After treatment of VL with antileishmanial drugs, the
immune response changes to a predominantly Th1 re-
sponse characterized by the presence of IL-12 produc-
tion by antigen presenting cells and INF-γ production by
T cells [24, 25]. Macrophage activation with subsequent
killing of parasites is the key factor [19]. In addition
to killing of parasites, commonly used antileishmanial
drugs have immunomodulatory properties. Reduction
of IL-10 and TGF-β occurs after treatment with stibo-
gluconate (SSG), but this effect is stronger in patients
treated with AmBisome or Fungisome, a locally pro-
duced liposomal amphotericin B from India, that
causes down regulation of IL-10, TGF-β and IL-12
[26]. Miltefosine stimulates T cells and macrophages
in vitro; in contrast to SSG, this was found to be non
T-cell dependent in the mouse model [27, 28]. In vivo
the LST becomes positive 6 months after treatment
in 80 % of patients and this is thought to be a
marker of immunity [2]. While from a clinical point
of view this immunity seems permanent, the LST
may revert back to negative [29]. It is not clear to
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what extent repeated exposure has a booster effect. In
addition, any condition that decreases immune re-
sponses such as HIV infection, diseases that cause
immunosuppression (e.g. haematological malignancies)
or immunosuppressive therapy (steroids, immuno-
modulators), may be a risk factor for primary VL or a
relapse of a previous VL episode as sterile cure prob-
ably does not exist. The humoral response gradually
decreases but antibodies may persist for months and
this makes serological tests less useful for monitoring
disease outcome or predict relapse [30].
PKDL
PKDL is characterized by an intermediate position be-
tween a Th2 and Th1 response and this translates into
the typical clinical features. As a result of antileishmanial
treatment of VL, the PKDL patient is no longer system-
ically ill, has no fever and the liver and spleen are no
longer enlarged. Only in the skin parasites persist that
may have been there since VL [31]. The immune re-
sponse in PKDL is thus (partly) characterized by im-
mune (re-)constitution, while at the same time there is
dissociation of the immune response between the skin
and the viscera. This causes the typical skin rash in the
absence of systemic illness [1].
In PKDL the Th2 response shows the presence and
persistence of IL-10 in the skin that was already present
during VL, while systemically the Th1 response that was
induced after VL therapy persists with IFN-γ produc-
tion.[32–34]. In the skin, as typically the PKDL lesions
occur in sun exposed areas of the skin (face, neck), the
immune response is thought to be related to the influ-
ence of UV light; this causes damage to dendritic cells
resulting in a Th2 type of response by inhibition of regu-
latory T cells. [32, 35–37] In PKDL increased levels of
IL-10 expressing CD3+CD8+ regulatory cells were found
in the skin that decrease after treatment [7]. Increased
numbers of circulating CD8 lymphocytes showed im-
paired proliferation that was restored after treatment.
This suggests that while overall in PKDL the CMI is in-
tact (after stimulation with phytohaemagglutinin or
Leishmania donovani antigen) and similar to healthy
controls and cured VL patients, subtle differences exist
[7, 35]. Other cells also produce cytokines and TGF –β,
TNF-α, IL-10 and IL-12 produced by keratinocytes play
a major role. While TNF-α levels are high, both in PKDL
and VL low levels of TNF-α receptor 1 (TNFR1) were
found, possibly caused by interference of high levels of
IL-6 [38]. The ratio of TNF-α (inflammatory): IL-10
(anti-inflammatory) message was 2.66 and 1.18 in
PKDL (skin biopsies) and VL (bone marrow aspirates),
respectively, showing the importance of the dynamics
of the cytokine profiles in various disease manifesta-
tions [38].
Macrophages are polarized to an M2 type (alternative
activation) that is associated with suppression of cell me-
diated immunity and disease chronicity. Raised vitamin
1α,25 dihydroxyvitamin D3 levels possibly produced by
the sun exposed skin in PKDL may play a role in the
abnormal macrophage differentiation [39]. Matrix metal-
loproteinases (MMP) that are induced by TNF-α are in-
volved in leucocyte recruitment and tissue remodeling
may be important as well as inhibitors thereof (TIMP
tissue inhibitor of matrix metalloproteinase) that are in-
duced by IL-10. Serum levels of MMP9 and the ratio of
MMP9 to TMIP1 (MMP9/TMIP1) are raised in active
PKDL and return to normal in healed PKDL patients
[38, 40]. TMIP3 is significantly elevated in PKDL com-
pared to VL and is suggested to play a role in confine-
ment of parasites to the skin in PKDL [38].
Th17 responses cause up regulation of Th17 markers
such as IL-17, which is an inducer of TNF-α and NO
levels in the PKDL lesion and in the blood; this is re-
versed by chemotherapy [41]. The differentiation into
IL-17 secreting Th17 cells is induced by IL-23 as well as
IL-1, IL-6 and TGF-β [41].
In human PKDL, miltefosine modulates the cytokine
response by increasing levels of pro-inflammatory cyto-
kines and decreasing anti-inflammatory cytokines; mac-
rophages are activated [27, 28].
From a clinical point of view, the immune response
that may vary over time and may differ between patients,
dictates the clinical manifestation. The strength of the
cell mediated immune response (CMI) is higher in acute
PKDL, whereas chronic PKDL is associated with a
weaker response [42]. Similarly, in macular PKDL the
CMI is strong with few parasites and low antibody levels
(only Ig1 is elevated), while in the polymorphic form
(papulo-nodular) the CMI is low, induced by TGF- β
and IL-10, with higher levels of markers for regulatory T
cells, more parasites and high antibody levels, including
both Ig1 and Ig3 (markers for IL-10) [36, 42–44]. Re-
cently, immune complexes that were identified by PEG
ELISA differed in quality and quantity between VL and
PKDL with an association between IgG1 containing im-
mune complexes found in VL and increased risk of sub-
sequent PKDL [45].
Clearly the immunological changes described are dy-
namic and these have not yet been captured fully in
available reports. There are no data that accurately de-
scribe the interval between VL and the development of
PKDL (or absence thereof ) in terms of immune re-
sponses, taking into account various parameters that
may influence this. While in Sudanese PKDL the im-
mune responses between VL and PKDL may form a
continuum as the interval is short, this is difficult to
understand in Asian PKDL in whom the interval may be
1–3 years or longer. It is not clear what happens
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between VL and PKDL and whether for example a pre-
dominantly Th1 response may revert to a Th2 type of
response and why this would happen (Fig. 3). The possi-
bility of a re-infection in a (partially) immune treated VL
patient should be considered.
Risk factors for PKDL in relation to immune
responses
Drug treatment for VL
In a study from Sudan a PKDL rate of 69 % was found
in those treated with erratic doses of sodium stibogluco-
nate (SSG) often of doubtful quality, whereas in those
who received supervised treatment (SSG 20 mg/kg for
15 days) the PKDL rate was only 35 % [46]. Short course
and high dose regimens seem to lower the PKDL rate as
was shown for paromomycin [47]. In India, resistance
for stibogluconate is common and PKDL rates decreased
after introduction of amphotericin B as first line treat-
ment for VL [43, 48]. These studies indicate that ad-
equate treatment is important not only for killing of
parasites but also for the development of an adequate
immune response.
PKDL has been reported after VL treatment with sti-
bogluconate, ambisome, miltefosine and paromomycin,
but the exact PKDL rate after each drug is unknown as
there are no studies with active follow-up [49–52]. In
India, in a retrospective study of VL patients treated
with AmBisome 20 mg/kg total dose, the cure rate for
VL was 99.3 % with a 0.3 % PKDL rate [51]. In
Bangladesh, a total dose of 15 mg/kg AmBisome for VL
resulted in a PKDL rate of 10 % in a prospective study
(Koert Ritmeijer, MSF-Holland, personal communica-
tion). In the South-East Asia region kala-azar elimin-
ation programme, single dose ambisome (SDA, 10 mg/
kg) is one of the pillars and has excellent cure rates for
VL of > 95 %; the PKDL rate is not known [53],
(www.searo.who.int/entity/vector_borne_tropical_diseases/
documents/SEA-CD-239/en/). In VL, a single dose of
ambisome leads to lower parasite clearance compared
with multiple dosing, but it is currently unclear whether
PKDL rates are significantly lower in those with longer
treatment duration [43, 54]. There is no information
about combination treatment.
Parasites
PKDL seems restricted to patients infected with L. dono-
vani and this corresponds with the main epidemiological
distribution in India and Africa. It should be noted, how-
ever, that the strains of L. donovani are completely dif-
ferent in these two regions from a molecular point of
view [55, 56]. No evidence exists that directly links para-
sites in various regions to features of PKDL. It should be
noted, however, that parasites that have developed resist-
ance to e.g. stibogluconate (Sb) lead to poor outcome of
VL and higher PKDL rate, probably mediated by a poor
immune response. This was demonstrated in India,
when changing from stibogluconate to amphotericin in
the treatment of VL this seemed to reduce the occur-
rence of PKDL [48]. In vitro experiments show that Sb-
resistant strains produce higher levels of IL-10 and
TGF-β after interacting with PBMCs and block SAG-
induced dendritic cell activation/ maturation; as these
Fig. 3 Schematic representation of clinical presentation, corresponding immune responses and areas of missing information using the Th1/Th2
dichotomy. *Most important parameters that determine the immunologically relevant response. a, b the intervals differ in time between regions:
0–13 months in Africa; 0–3 years in Asia. There is limited information on (the timing of) the developing or changing immune response in relation
to type of VL treatment (or in case of absent VL history) and the clinical response (macular, papular, nodular PKDL; distribution and severity). c the
interval after successful treatment of VL and establishment of permanent immunity is unknown. d, e there is no information on (the timing of)
the developing or changing immune response (after PKDL treatment or after self-healing), the clinical response (reduction or disappearance of
lesions) and development of immunity
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findings may also play a role in the pathophysiology of
PKDL, further studies seem warranted [57, 58].
PKDL is rarely reported after VL caused by L. infan-
tum or L. tropica infection unless there is co-infection
with HIV [59, 60].
Although molecular analysis has shown differences be-
tween L. donovani strains in VL and PKDL probably as
a result of antileishmanial drug treatment, they seem to
be similar in terms of pathogenicity. PKDL strains keep
their visceralizing ability in mice, providing support for
the immune response as the main determinant for clin-
ical manifestations (PKDL) [61–63].
Genetics
Genetic factors may be responsible for the differences
between endemic regions with regard to clinical and epi-
demiological findings. This was shown for the decreased
function of the interferon-gamma receptor 1 gene
(IFNGR1) that was found linked to development of
PKDL in Sudan; this was not found for VL [64]. This
was also detected in PKDL skin biopsies with uniform
low expression of IFN-γ and IFNGR1, possibly explain-
ing the persistence of parasites. Similar downregulation
of the IFN-γ receptor was found in biopsies in a study
from India [38, 65].
So far there has been no evidence for polymorphisms
in the IL 10 gene promotor [65].
VL and PKDL and immunosuppression
Leishmaniasis is not uncommon in patients who are im-
munosuppressed. HIV co-infection is the most common
cause; other conditions include patients with organ
transplants or who are on immunosuppressive or immu-
nomodulatory therapy, including the use of topical ste-
roids [66, 67]. PKDL with concomitant HIV infection is
more common and more severe [68]. All patients re-
ported with PKDL and HIV co-infection had a CD4
count of less than 350 cells/mm3; in 95 % this count was
less than 200 cells/ mm3 [59]. PKDL is no longer re-
stricted to L. donovani and has been described in VL
caused by L. infantum and L. tropica. Up to 30 % of
HIV-VL co-infected patients have skin lesions resem-
bling PKDL lesions but are more pronounced. Nodular
lesions are common and florid and more extensive with
unusual distribution; the acra are commonly involved.
Hyperpigmentation and scaling may occur. Numerous
parasites can be demonstrated in aspirates. Lesions may
resemble Kaposi’s sarcoma or psoriasis; others may
occur in pre-existing dermal conditions such as derma-
tofibroma, Kaposi’s sarcoma or even tattoos. HIV co-
infected VL or PKDL patients could play a major role in
transmission because of the high parasite load in the
skin, the viscera and the blood [59]. The lesions may
precede, coincide with or follow VL [59]. It is not always
clear if PKDL follows VL or presents concomitantly with
visceral disease (para kala-azar dermal leishmaniasis) or
whether PKDL has regressed to VL [59]. In HIV co-
infection the delineation between VL, PKDL and (dis-
seminated) cutaneous leishmaniasis e.g. caused by L.
major or L. tropica becomes blurred as cutaneous leish-
maniasis may visceralize [59].
HIV infection and leishmaniasis both target macro-
phages and dendritic cells; HIV targets CD4 cells dir-
ectly while Leishmania does this indirectly by promoting
HIV replication in CD4 cells that play a pivotal role in
the immune response needed to combat both infections;
this leads to a predominant and aggravated Th2 immune
response. In VL clinically this translates into a state of
profound immune suppression with high parasitaemia
and unusual clinical presentations. In HIV-VL co-
infection the Th2 response that is characteristic of VL
is exaggerated with decreased levels of IL-12 and IL-
18 and interferon-γ, which is the adequate milieu for
PKDL [69]. The Th17 cells subset response is lost
earlier than that of Th1 cells [70].
Co-infected VL or PKDL patients are treated simultan-
eously with antileishmanial and antiretroviral therapy
(ART). In some patients PKDL seems to occur in the
context of immune (re)constitution as a result of ART,
although it may have resulted from antileishmanial
therapy only as both treatments may lead to immune
(re-)constitution. Management is compounded by high
recurrence rates. In some patients the CD4 cell count
remains low despite successful antiretroviral therapy
with undetectable viral load. AmBisome is the drug of
choice for treatment of VL while intermittent AmBi-
some, stibogluconate or pentamidine have been consid-
ered as maintenance therapy, e.g. every 3–4 weeks [71].
Immune manipulation in PKDL
Because of the incomplete immune response, combined
antileishmanial therapy and immunomodulation has
been studied. The autoclaved L. major vaccine did not
prove to have sufficient immunogenicity to prevent CL
and VL, in studies in Iran and Sudan, respectively [72,
73]. A next generation alum-precipitated autoclaved L.
major vaccine was shown to be more immunogenic in
healthy volunteers and was studied in chronic PKDL
cases in Sudan who failed previous treatment with stibo-
gluconate [74]. In those who were treated with SSG and
vaccine, the cure rate after 6 months was 86 % while for
those treated with SSG only, this was 53 % [75].
The rationale for immune manipulation is clear from a
pathophysiological point of view. Currently prolonged
courses with stibogluconate or miltefosine are given
mainly aiming at killing of parasites and these drugs also
have immunomodulatory effects. While in patients with
chronic or disfiguring PKDL the indication for treatment
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is clear, in those with milder lesions any drug needs to
have a good safety profile as the patients are not system-
ically ill or at risk of dying; in addition in Africa (Sudan)
most of the patients will self-heal in 12 months. A safe
immunomodulatory agent would target the immuno-
logical block and push towards a Th1 response. It could
be argued that such an agent could also be added to VL
treatment to achieve the Th1 response quickly so as to
prevent PKDL from occurring. Currently, it seems that
in the Indian subcontinent PKDL rates do not drop
below 10 % despite VL therapy with excellent VL cure
rates making combined immunochemotherapy an at-
tractive option. Anti-IL-10 signaling blockade with
monoclonal antibody is a candidate that was found to
improve parasite-specific IFN-γ in patients with VL [76].
Further studies with similar compounds are expected.
Conclusion
PKDL is an immunologically mediated condition and
further understanding of the immune responses at vari-
ous stages of clinical VL and PKDL, as well as in cure
and during asymptomatic intervals is essential. PKDL is
not a static or uniform disease and each patient may be
different in terms of clinical presentation, chronicity,
underlying immunological parameters, tendency to self-
heal or response to drug therapy. Factors regarding drug
therapy used, co-infections and genetics may therefore
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